Paige, the computational pathology startup targeting cancer, closes Series B at $70M

Paige, the startup that spun out of the Memorial Sloan Kettering Cancer Center and launched in 2018 to help advance cancer research and care by applying AI to better understand cancer pathology, is today announcing a milestone in its growth story: it has raised a further $20 million from Goldman Sachs and Healthcare Venture Partners, closing out its Series B at $70 million.
Leo Grady, Paige’s CEO, says the funding will go towards several areas.
It will be used for hiring; to continue expanding its partnerships with biopharmaceutical companies (deals that have not yet been made public); and to continue investing in clinical work, based around algorithms it has built and trained using more than 25 million pathology slides in MSK’s archive, plus IP related to the AI-based computational pathology that underpins Paige’s work. It will also be used to help it expand to the UK and Europe. Paige has a CE mark to be used clinically in both regions and the startup already has beta sites in the UK and EU, but it hasn’t had a fully commercial launch in either region, Grady said.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2020    »